17:17:19 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Lundbeck är ett läkemedelsbolag. Störst fokus återfinns inom forskning om psykiatriska och neurotiska störningar, vilket innefattar behandling av depression, schizofreni, Alzheimers och Parkinsons syndrom. Bolaget bedriver forskning, utveckling och vidare distribution av läkemedel där kunderna återfinns på global nivå. Bolaget grundades 1915 och har sitt huvudkontor i Valby.

Kalender

2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Split HLUN B 1:5
2022-06-08 Extra Bolagsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-03-24 Ordinarie utdelning HLUN B 2.00 DKK
2022-03-23 Årsstämma 2022
2022-02-09 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-11 Kvartalsrapport 2021-Q1
2021-03-24 Ordinarie utdelning HLUN B 2.50 DKK
2021-03-23 Årsstämma 2021
2021-02-04 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-12 Kvartalsrapport 2020-Q1
2020-03-25 Ordinarie utdelning HLUN B 4.10 DKK
2020-03-24 Årsstämma 2020
2020-02-06 Bokslutskommuniké 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-08-14 Kvartalsrapport 2019-Q2
2019-05-08 Kvartalsrapport 2019-Q1
2019-03-27 Ordinarie utdelning HLUN B 12.00 DKK
2019-03-26 Årsstämma 2019
2019-02-05 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-08 Kvartalsrapport 2018-Q1
2018-03-21 Ordinarie utdelning HLUN B 8.00 DKK
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-09 Kvartalsrapport 2017-Q2
2017-05-10 Kvartalsrapport 2017-Q1
2017-03-31 Ordinarie utdelning HLUN B 2.45 DKK
2017-03-30 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-11-02 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-11 Kvartalsrapport 2016-Q1
2016-04-01 Ordinarie utdelning HLUN B 0.00 DKK
2016-03-31 Årsstämma 2016
2016-02-10 Bokslutskommuniké 2015
2015-11-04 Kvartalsrapport 2015-Q3
2015-08-19 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-03-26 Ordinarie utdelning HLUN B 0.00 DKK
2015-03-25 Årsstämma 2015
2015-02-05 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-07 Kvartalsrapport 2014-Q2
2014-05-07 Kvartalsrapport 2014-Q1
2014-03-27 Ordinarie utdelning
2014-03-26 Årsstämma 2014
2014-02-06 Bokslutskommuniké 2013
2013-11-06 Kvartalsrapport 2013-Q3
2013-08-07 Kvartalsrapport 2013-Q2
2013-05-01 Kvartalsrapport 2013-Q1
2013-03-22 Ordinarie utdelning
2013-03-21 Årsstämma 2013
2013-02-06 Bokslutskommuniké 2012
2012-03-30 Ordinarie utdelning
2011-03-31 Ordinarie utdelning
2010-04-21 Ordinarie utdelning
2009-04-22 Ordinarie utdelning
2021-11-29 15:00:00

Valby, Denmark, November 29, 2021 - H. Lundbeck A/S (Lundbeck) announces that Jacob Tolstrup, Executive Vice President for Commercial Operations, is promoted to Chief Commercial Officer, effective 1 January 2022. Jacob will be responsible for sales and marketing across all Lundbeck affiliates worldwide.

Peter Anastasiou, Executive Vice President for North America, has decided to leave Lundbeck at the end of the year for another career opportunity that will be announced in the near future.

"I am pleased that we have internal talent to step up to the Chief Commercial Officer role. We will immediately benefit from Jacob's in-depth knowledge of Lundbeck and extensive experience in global markets. Consolidating all our affiliates into one organization will enable us to seamlessly coordinate across our markets as we forge ahead with executing our strategy. I would like to take this opportunity to thank Peter for his many years of service to Lundbeck and to our patients. He has been an asset to our leadership team, instrumental in growing North America and he departs us with our North America business in a position of strength. I wish him every success in his future endeavors," said Deborah Dunsire, CEO of Lundbeck.

Jacob Tolstrup has been with Lundbeck for over 20 years and has held a variety of roles and management positions across the company. He has been a member of the Executive Management team at Lundbeck since 2012. During his career, Jacob spent 4 years in the United States including a period as Head of Finance between 2010-2012. Since 2017, Jacob has been Executive Vice President, Head of Commercial Operations, which includes Global Strategic Marketing and all markets outside of North America (Europe and International Markets).

Jacob holds a Master of Science in Business Administration and Commercial Law as well as an MBA. He also serves as Chairman of the Board of Directors of Pharmacosmos A/S.

As of January 2022, the Executive Board will consist of:
  •                             Deborah Dunsire, President and CEO

  •                             Anders Götzsche, Executive Vice President, Chief Financial Officer

  •                             Johan Luthman, Executive Vice President. Head of R&D

  •                             Jacob Tolstrup, Executive Vice President, Chief Commercial Officer

  •                             Lars Bang, Executive Vice President, Product Development & Supply

  •                             Keld Flintholm Jørgensen, Executive Vice President, Strategy & Business Development

  •                             Elise Hauge, Executive Vice President, People & Communication 

 

Lundbeck contacts

Investors: Media:
                                   
Palle Holm Olesen Thomas Mikkel Mortensen
Vice President, Investor Relations Media Relations Lead, Corp. Communication
PALO@lundbeck.com THMR@lundbeck.com (thmr@lundbeck.com)
+45 30 83 24 26 +45 30 83 30 24

About H. Lundbeck A/S
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Instagram (h_lundbeck), Twitter at @Lundbeck andvia LinkedIn. 

Safe Harbor/Forward-Looking Statements
This corporate release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation. Lundbeck does not undertake any obligation to update or revise forward-looking statements in this presentation or oral presentations made on behalf of Lundbeck, nor to confirm such statements to reflect subsequent events or circumstances after the date of the presentation or in relation to actual results, unless otherwise required by applicable law or applicable stock exchange regulations.